News J&J jumps on the MFN pricing train Johnson & Johnson is the latest pharma group to agree a Most-Favoured Nation (MFN) drug pricing deal with the Trump administration to avert tariffs.
News CMS aims for broader GLP-1 access via federal programmes CMS has revealed a new, voluntary access programme that aims to broaden the use of GLP-1 agonist medicines for diabetes and obesity.
News Nine more companies sign pricing deals with Trump Nine more pharma groups have agreed to lower the costs of medicines in the US under the Trump administration's most favoured nation (MFN) scheme.
Market Access How are the US MFN and German MFG likely to impact pharmaceu... A comparison of the US MFN and German MFG.
Patients How direct-to-patient prescribing is shifting the status quo... To remain competitive, biopharma must move beyond disjointed support services and take direct responsibility for the patient journey.
News MFN model for Medicaid revealed by CMS The Trump administration has released details of a most-favoured nation (MFN) drug pricing programme for medicines provided by Medicaid.
News J&J jumps on the MFN pricing train Johnson & Johnson is the latest pharma group to agree a Most-Favoured Nation (MFN) drug pricing deal with the Trump administration to avert tariffs.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
